Trial Profile
Planned trial of Novan's CR 2016, nitric oxide-releasing product using Nitricil technology, in patients with chronic wound infections caused by multi-drug resistant bacteria
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 22 Oct 2014
Price :
$35
*
At a glance
- Drugs CR 2016 (Primary)
- Indications Chronic wounds; Gram-negative infections; Wound infections
- Focus Therapeutic Use
- Sponsors Novan Inc
- 22 Oct 2014 New trial record
- 19 Aug 2014 This trial is expected to be initiated in the first half of 2015, according to a Novan media release.